potassium phosphates in sodium chloride
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE (potassium phosphates in sodium chloride) by Amneal Pharms is tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization. First approved in 2024.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
Potassium Phosphates in 0.9% Sodium Chloride is an intravenous electrolyte replacement solution that restores critical phosphate levels in patients with deficiency or depletion. The drug works by replenishing phosphate stores essential for nucleic acid synthesis, energy metabolism, cell signaling, and bone mineralization. It addresses a vital physiologic need in hospitalized and critically ill populations requiring parenteral nutrition or electrolyte correction.
Early-stage growth trajectory with minimal competitive pressure; commercial team likely small but expanding to establish hospital formulary adoption and supply chain partnerships.
tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
This product offers career entry or lateral movement into specialized hospital/critical care commercial roles with low immediate competitive complexity but high adoption-focused challenges. Success depends on formulary penetration, hospital relationships, and clinical evidence building rather than direct-to-patient marketing or high-volume sales.
Worked on POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo